{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T11:20:47Z","timestamp":1705490447967},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1007\/s00105-006-1179-7","type":"journal-article","created":{"date-parts":[[2006,7,27]],"date-time":"2006-07-27T15:12:48Z","timestamp":1154013168000},"page":"338-342","source":"Crossref","is-referenced-by-count":5,"title":["Steroidaggravierte Rosazea"],"prefix":"10.1007","volume":"58","author":[{"given":"N.","family":"Meykadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. C.","family":"Marsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1179_CR1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archderm.140.4.457","volume":"140","author":"Antille","year":"2004","unstructured":"Antille C, Saurat JH, L\u00fcbbe J (2004) Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 140: 457\u2013460","journal-title":"Arch Dermatol"},{"key":"1179_CR2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14656566.2.7.1167","volume":"2","author":"Assmann","year":"2001","unstructured":"Assmann T, Homey B, Ruzicka T (2001) Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother 2: 1167\u20131175","journal-title":"Expert Opin Pharmacother"},{"key":"1179_CR3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0190-9622(03)02157-1","volume":"50","author":"Bamford","year":"2004","unstructured":"Bamford JT, Elliott BA, Haller IV (2004) Tacrolimus effect on rosacea. J Am Acad Dermatol 50: 107\u2013108","journal-title":"J Am Acad Dermatol"},{"key":"1179_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijpharm.2003.07.013","volume":"269","author":"Billich","year":"2004","unstructured":"Billich A, Aschauer H, Aszodi A, Stuetz A (2004) Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 269: 29\u201335","journal-title":"Int J Pharm"},{"key":"1179_CR5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2133.2005.06404.x","volume":"152","author":"Chu","year":"2005","unstructured":"Chu CY (2005) The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 152: 396\u2013399","journal-title":"Br J Dermatol"},{"key":"1179_CR6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1540-9740.2005.03740.x","volume":"4","author":"Crawford","year":"2005","unstructured":"Crawford KM, Russ B, Bostrom P (2005) Pimecrolimus for treatment of acne rosacea. Skinmed 4: 147\u2013150","journal-title":"Skinmed"},{"key":"1179_CR7","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.0007-0963.2004.05884.x","volume":"150","author":"Dissemond","year":"2004","unstructured":"Dissemond J, Schr\u00f6ter S, Franckson T et al. (2004) Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. Br J Dermatol 150: 782\u2013784","journal-title":"Br J Dermatol"},{"key":"1179_CR8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jaad.2005.04.053","volume":"54","author":"El","year":"2006","unstructured":"El Sayed F, Ammoury A, Dhaybi R, Bazex J (2006) Rosaceiform eruption to pimecrolimus. J Am Acad Dermatol 54: 548\u2013550","journal-title":"J Am Acad Dermatol"},{"key":"1179_CR9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1067\/mjd.2001.114739","volume":"44","author":"Goldman","year":"2001","unstructured":"Goldman D (2001) Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 44: 995\u2013998","journal-title":"J Am Acad Dermatol"},{"key":"1179_CR10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jpag.2003.11.013","volume":"17","author":"Goldstein","year":"2004","unstructured":"Goldstein AT, Marinoff SC, Christopher K (2004) Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 17: 35\u201337","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"1179_CR11","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archderm.141.9.1168","volume":"141","author":"Gorman","year":"2005","unstructured":"Gorman CR, White SW (2005) Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch Dermatol 141: 1168","journal-title":"Arch Dermatol"},{"key":"1179_CR12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000071799","volume":"207","author":"L","year":"2003","unstructured":"L\u00fcbbe J, Stucky L, Saurat JH (2003) Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology 207: 204\u2013205","journal-title":"Dermatology"},{"key":"1179_CR13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00105-003-0556-8","volume":"54","author":"Meykadeh","year":"2003","unstructured":"Meykadeh N, Hengge UR (2003) Topical immunomodulators in dermatology. Hautarzt 54: 641\u2013661","journal-title":"Hautarzt"},{"key":"1179_CR14","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2133.2004.06208.x","volume":"151","author":"Rigopoulos","year":"2004","unstructured":"Rigopoulos D, Ioannides D, Kalogeromitros D et al. (2004) Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 151: 1071\u20131075","journal-title":"Br J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1179-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-006-1179-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1179-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:37:11Z","timestamp":1558582631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-006-1179-7"}},"subtitle":["Erfolgreiche Therapie mit Pimecrolimus"],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1007\/s00105-006-1179-7","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}